Loading...
•
Mar 31
Moderna Q1 2025 Earnings Report
Moderna reported a net loss and decreased revenue in Q1 2025 due to seasonality and reduced COVID-19 vaccine demand.
Key Takeaways
Moderna saw a decline in revenue and continued net losses in Q1 2025, attributed to lower vaccination rates and the seasonal nature of its respiratory business. Despite financial challenges, the company is progressing on a robust pipeline, including oncology and rare disease candidates.
Total revenue dropped to $108,000,000 from $167,000,000 YoY, driven by reduced product sales.
Net loss was $(1,000,000,000) with an EPS of $(2.52).
Company expects to reduce operating costs by up to $1.7 billion by 2027.
Advancing up to 10 products toward approval, with strong focus on oncology and rare diseases.
Moderna
Moderna
Moderna Revenue by Segment
Moderna Revenue by Geographic Location
Revenue by Segment
Product Sales Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Moderna reaffirmed its 2025 revenue outlook and continues to anticipate a seasonal uplift in the second half of the year while executing a cost reduction strategy.
Positive Outlook
- 2025 revenue guidance maintained at $1.5 to $2.5 billion
- Year-end cash expected to be approximately $6 billion
- Cost of sales projected at $1.2 billion for 2025
- R&D spending expected to be approximately $4.1 billion
- Advancing 10 products, including several late-stage programs
Challenges Ahead
- First half 2025 revenue expected to be only $200,000,000
- High cost of sales relative to product revenue in Q1
- Operating loss continues to impact cash reserves
- CMV vaccine study did not meet early efficacy criteria
- FDA extended timeline for flu/COVID combo vaccine approval